The action of SRT1720 on myeloma cells also increases the concentration of ATM kinase (ataxia-telangiectasia mutated kinase) and increases its ability to interact with the effector kinase involved in DNA repair—checkpoint kinase 2 (CHEK2)—which leads to cell death induced by this complex. Here, CHEK2 is linked to plasma cell myeloma.